Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase

Carcinogenesis

Volumn 29, Issue 12, 2008, Pages 2369-2376

  Hu, Xiao Men ^a   Meng, Dan ^a   Fang, Jing ^a  

^a Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; FOCAL ADHESION KINASE; GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN TARGETING;

ACTINS; ANIMALS; ANTINEOPLASTIC AGENTS; APIGENIN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 57349181198     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn244     Document Type: Article

References (31)

1. Sieg,D.J. et al. (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol., 2, 249-256.
2. SchlaepferD.D. et al. (2004) Control of motile and invasive cell pheno-types by focal adhesion kinase. Biochim Biophys. Acta, 1692, 77-102.
3. McLean,G.W. et al. (2005) The role of focal-adhesion Idnase, in cancer - a new therapeutic opportunity. Nat. Rev. Cancer, 5, 505-515.
4. Schaller,M.D. (2001) Biochemical signals and biological responses elicited by the focal adhesion Idnase. Biochim Biophys. Acta, 1540, 1-21.
5. Frisch,S.M. et al. (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. J. Cell Biol., 134, 793-799.
6. Jemal,A. et al. (2005) Cancer statistics. CA Cancer J. Clin. 55, 10-30.
7. Sood,A.K. et al. (2004) Biological significance of focal adhesion kinase in ovarian cancer: Role in migration and invasion. Am. J. Pathol., 165, 1087-1095.
8. Judson,P.L. et al. (1999) Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma. Cancer, 86, 1551-1556.
9. Duthie,G. et al. (2000) Plant-derived phenolic antioxidants. Curr Opin. Clin. Nutr. Metab. Care, 3, 447-451.
10. Gupta,S. et al. (2001) Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem. Biophys. Res. Conunun., 287 914-920.
11. Wang,W. et al. (2000) Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell tines. Mol. Carcinog., 28, 102-110.
12. Zheng,P.W. et al. (2005) Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sci. 76, 1367-1379.
13. Way,T.D. et al. (2004) Apigenin induces apoptosis through proteasomal degradation of IIER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J. Biol. Chem., 279, 4479-4489.
14. Czyz,J. et al. (2005) Flavonoid apigenin inhibits motility and invasiveness of carcinoma cells in vitro. Int. J. Cancer, 114 12-18.
15. Lindenmeyer,F. et al. (2001) Apigenin acts on the tumor cell invasion process and regulates protease production. Nutr Cancer, 39, 139-147.
16. Fang,J. et al. (2007) Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis, 28 858-864.
17. Carmichael,J. et al. (1987) Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res., 47, 936-942.
18. Meng,Q. et al. (2006) Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell. Signal., 18, 2262-2271.
19. Kiguchi,K. et al. (1998) A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin. Exp. Metastasis, 16, 751-756.
20. Liu,L.Z. et al. (2005) Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol. Pharmacol., 68, 635-643.
21. Shukla,S. et al. (2005) Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J., 19 2042-2044.
22. Ilic,D. et al. (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544.
23. Westhoff,M.A. et al. (2004) SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol. Cell. Biol., 24, 8113-8133.
24. Sekine,Y. et al. (2007) Signal-transducing adaptor protein-2 regulates integrin-mediated T cell adhesion through protein degradation of focal adhesion kinase. J. Immunol., 179, 2397-2407.
25. Mitra,S.K. et al. (2005) Focal adhesion kinase: In command and control of cell motility. Nat. Rev. Mol. Cell Biol., 6, 56-68.
26. Chien,J.R. et al. (2007) Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J. Cell. Biochem., 102 1117-1129.
27. Halder,J. et al. (2005) Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin. Cancer Res., 11, 8829-8836.
28. Halder,J. et al. (2006) Focal adhesion kinase targeting using in vivo short interfering-RNA delivery in neural liposomes for ovarian carcinoma therapy. Clin. Cancer Res., 12, 4916-4924.
29. Grisaru-Granovsky,S. et al. (2005) Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int. J. Cancer, 113, 372-378.
30. Schiaepfer,D.D. et al. (1994) Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase. Nature, 372, 786-791.
31. Patel,D. et al. (2007) Apigenin and cancer chemoprevention: progress, potential and promise (review), Int. J. Oncol., 30 233-245.